E-mail Registration

Request More Information

If you are a patient and your question is about a medical condition, then you should consult with a healthcare professional, or in the case of an emergency, call 911 immediately. Please Contact Us for additional information.

Yes, I would like to receive information about Humate-P^®, von Willebrand disease, and CSL Behring products, programs, and services.

All fields marked with an asterisk (*) are required.

*Salutation:

*Suffix:

*First Name:

*Last Name:

*I am a:

*Specialty:

*This is my:

Home Address
Work Address

*Address 1:

Address 2:

*City:

*State:

*ZIP Code:

Telephone Number:

*E-mail Address:

*Confirm E-mail Address:

I am a Health care Professional and have questions about the information I just requested and would like a CSL Behring representative to contact me by:
Phone
E-mail

*My key area of interest is (check all that apply):
Hemophilia A
Hemophilia B
von Willebrand disease

Educational Materials

I would like the following educational materials sent to me. (If you would like to request additional quantities please contact Consumer Affairs at 1-888-508-6978.)

Humate-P^® Brochure—This 16-page brochure provides essential information on the safety and efficacy of Humate-P^®.

Desktop Flip Chart—This useful chart describes the role of von Willebrand factor (VWF) in platelet adhesion and aggregation, and presents treatment options for VWD.

Diagnosing VWD—Many people with VWD are asymptomatic and the majority are undiagnosed. This brief guide provides the latest guidelines for diagnosing VWD.

Dosage Calculator—This convenient, pocket-size version of our dosage calculator determines the correct Humate-P^® dose needed to achieve the desired increase in circulating VWF.

For Your Patients:

Introducing You to VWD and Humate-P^®—This brochure offers newly diagnosed patients help in managing their condition while providing important information about Humate-P^® as a treatment option.

Humate-P^® Consumer Brochure—For patients who want a more in-depth look at Humate-P^®, this brochure discusses high molecular weight multimers, the viral safety of Humate-P^®, and the clot formation process.

Patient's Guide to Understanding VWD—This booklet talks about the disorder, symptoms, and diagnosis, and provides general information on treatment options.

VWD, Menstruation, and Your Daughter—Women with VWD may experience menorrhagia during menstruation, and this booklet helps parents explain to their pre-teen daughters how VWD may affect them.

Diane Dino's Dilemma—This beautifully illustrated children's book tells the encouraging story of how a young dinosaur (Diane Dino) finds out she has VWD.

VWD Stay Healthy�Stay Active GIRLS Brochure—This brochure talks about menstruation. It also discusses the importance of regular physical activity, activities that girls can enjoy, activities that they should avoid, and a step-by-step process of how to get started.

VWD Stay Healthy�Stay Active BOYS Brochure—This brochure talks about VWD the disorder, activities that boys can enjoy, activities that they should avoid, and how to get started.

My Journal—This booklet discusses and answers questions about menstruation and also has an easy-to-use bleeding journal that allows you to keep track of your menstrual cycle.

How to Reconstitute Humate-P Using Mix2Vial Brochure—This useful brochure describes the step-by-step process of how to mix Humate-P^® using the Mix2Vial™ (needle-free transfer device).

Humate-P^® Mix2Vial™ Infusion Mat (English/Spanish)—This useful infusion mat describes the step-by-step process of how to mix Humate-P^® using the Mix2Vial™ (needle-free transfer device).

A Guide to Living With von Willebrand Disease—This book provides valuable information on living with the disease and was written by Renee Paper, RN, with Laureen A. Kelley.

Journal Reprints

Below is a list of informative and relevant journal articles provided as reprints by
CSL Behring. These articles are grouped by general topic and are designed to provide you and your patients with useful information on von Willebrand Disease (VWD) and the use of Humate-P^® in a clinical setting.

Please select from the following journal articles and CSL Behring will send the articles to you via USPS mail.

Efficacy and Safety of Humate-P^®

Lillicrap D, Poon M-C, Walker I, Xie F, Schwartz BA, and members of the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the Factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002;87:224-230.

Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P^®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia.
2003;9:688-695.

Treatment of VWD

Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med.
2004;351:683-694.

Characterization of VWF via Multimer Analysis

Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, M�ller H-G, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis.Haemophilia.
1998;4(suppl 3):25-32.

Women With VWD

Scharrer I. Women with von Willebrand disease. Hamostaseologie. 2004;24:44-49.

Philipp C, Faiz A, Dowling N, et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol. 105;61-66.

*Type in the verification word in the box below and hit "Submit":

Prior to submitting your information, please review our Privacy Policy.

I would like to unsubscribe from this e-mail program.

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P^® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P^® is also in indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P^® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see accompanying full prescribing information for Humate-P^®.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.

|||
||